Skip to main content
INNOCARE PHARMA LIMITED logo

INNOCARE PHARMA LIMITED — Investor Relations & Filings

Ticker · 688428 ISIN · CNE100005P56 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688428

About INNOCARE PHARMA LIMITED

https://www.innocarepharma.com/

InnoCare Pharma Limited is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of molecularly targeted therapies for cancer and autoimmune diseases. The company prioritizes the creation of first-in-class and best-in-class drugs to address significant unmet medical needs. Its flagship product, orelabrutinib, is a highly selective Bruton's tyrosine kinase (BTK) inhibitor utilized in the treatment of B-cell malignancies and investigated for autoimmune indications. InnoCare's pipeline includes a diverse range of candidates targeting solid tumors and hematological conditions, leveraging expertise in structural biology and precision medicine. The organization maintains integrated capabilities across research, clinical development, and manufacturing to support its global therapeutic programs.

Recent filings

Filing Released Lang Actions
诺诚健华医药有限公司自愿披露关于ICP-054（ZB021）完成首例受试者入组的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement disclosing clinical trial progress (first subject enrollment for drug candidate ICP-054) by the board. It contains no financial statements, no voting results, no management change, and no other specific filing type applies. It is thus a general regulatory announcement best classified as Regulatory Filings (RNS).
2026-05-13 Chinese
诺诚健华医药有限公司2025年度审计报告
Regulatory Filings
2026-03-25 Chinese
诺诚健华医药有限公司关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the revision of the company's Articles of Association (公司章程). It includes extensive text about amendments to the company's organizational rules, shareholder meeting procedures, voting rights, and other governance-related provisions. The content focuses on internal governance structure and rules rather than financial results, audit opinions, or capital changes. There is no indication of financial statements, earnings data, or audit reports. The document is not a notice of a meeting or voting results but a substantive update to governance documents. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-03-25 Chinese
InnoCarePharmaLimited（诺诚健华医药有限公司）提名委员会职权范围
Governance Information Classification · 95% confidence The document is a detailed description of the Nomination Committee's terms of reference, including definitions, establishment, membership, meeting procedures, responsibilities, reporting, and authority. It focuses on governance aspects such as board composition, director nomination, independence assessments, and succession planning. There is no financial data, earnings information, or regulatory filing announcements. The content aligns with governance practices and internal rules of the company rather than financial reporting or announcements. Therefore, the document fits best under Governance Information (CGR). The document length is 4033 characters, which is sufficient for a detailed governance report rather than a brief announcement.
2026-03-25 Chinese
InnoCarePharmaLimited（诺诚健华医药有限公司）股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting" of InnoCare Pharma Limited. It details the rules, procedures, and governance related to the conduct of shareholders' meetings, including powers of the shareholders' meeting, convening, proposals, voting, and representation. It does not contain financial statements, audit results, or earnings data. It is a governance document outlining internal rules and procedures for shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high due to the clear focus on governance rules for shareholder meetings.
2026-03-25 Chinese
诺诚健华医药有限公司关于调整募投项目内部投资结构的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 诺诚健华医药有限公司 regarding adjustments to the internal investment structure of its fundraising projects related to its initial public offering (IPO) on the A-share market. It details the changes in allocation of raised funds among various sub-projects, the reasons for these adjustments, and the impact on the company's operations. The document includes references to the board of directors' approval and the need for shareholder meeting approval. It also contains a sponsor institution's verification opinion. The document is not a full financial report, earnings release, or management discussion but rather a formal announcement about changes in the use of previously raised capital. This fits the definition of a Capital/Financing Update (CAP) as it updates on the company's fundraising capital usage and investment structure changes. The document length (6014 characters) and content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2026-03-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.